文献速递糖尿病

胰岛素分泌预测新诊断糖尿病患者的降糖治疗反应

Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究基于EDICT研究261例新诊断2型糖尿病患者的随机分组数据,通过75克口服葡萄糖耐量试验评估C肽比值(C-Pep120/C-Pep0)对降糖治疗反应的预测价值。结果显示该比值是治疗反应的最强预测因子:比值低于1.78者更可能需要胰岛素,高于2.65者更可能通过二甲双胍单药达标;初始三联治疗者的HbA1c下降与比值无关。

要点

  • C-Pep120/C-Pep0比值可预测新诊断T2DM患者对降糖药物的反应。
  • 比值低于1.78者更可能需要加用胰岛素控制血糖。
  • 比值高于2.65者更可能通过二甲双胍单药实现血糖控制。

核心结论

  • 葡萄糖负荷后C肽较空腹的增幅可预测新诊断糖尿病患者的降糖治疗反应。
  • C-Pep120/C-Pep0比值有助于新诊断T2DM患者降糖治疗的个体化选择。

研究设计与样本

  • EDICT研究为单中心随机研究,共纳入261例新诊断且未用药的T2DM患者。
  • 患者随机接受二甲双胍序贯加用格列吡嗪及甘精胰岛素治疗,或初始二甲双胍/吡格列酮/艾塞那肽三联治疗。
  • 所有患者在治疗开始前接受75克口服葡萄糖耐量试验。
  • 采用受试者工作特征曲线下面积方法识别治疗反应的预测因素。

主要发现

  • 54例患者需要在二甲双胍基础上加用格列吡嗪。
  • 47例患者需要在二甲双胍加格列吡嗪基础上加用胰岛素以控制血糖。
  • OGTT期间血浆C肽浓度比值C-Pep120/C-Pep0是治疗反应的最强预测因子。
  • 比值小于1.78者更可能需要胰岛素控制血糖,比值大于2.65者更可能通过二甲双胍单药实现血糖控制。

关键数值与推荐

  • C-Pep120/C-Pep0比值小于1.78提示更可能需要胰岛素控制血糖。
  • C-Pep120/C-Pep0比值大于2.65提示更可能通过二甲双胍单药实现血糖控制。
  • 治疗目标为HbA1c低于6.5%。

临床怎么用

  • 对新诊断T2DM患者可考虑行75克OGTT计算C-Pep120/C-Pep0比值以辅助降糖方案个体化。
  • 比值较低者宜较早考虑需要胰岛素的治疗策略,比值较高者可优先尝试二甲双胍单药。
  • 初始三联治疗者的疗效预测不依赖该比值。

局限性

  • 研究为单中心设计。
  • 原文未报告更多局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The results of the present study demonstrate that beta cell function in newly diagnosed T2DM patients is the key predictor of response to glucose lowering medications and provides a practical tool (C-Pep120 /C-Pep0) to guide the choice of glucose lowering agent. OBJECTIVE: This work aims to identify predictors for individualization of antidiabetic therapy in patients with new-onset type 2 diabetes mellitus (T2DM). METHODS: A total of 261 drug-naive participants in the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study, with new-onset diabetes, were randomly assigned in a single-center study to receive 1) metformin followed by glipizide and then insulin glargine on failure to achieve glycated hemoglobin A1c (HbA1c) less than 6.5%, or 2) initial triple therapy with metformin/pioglitazone/exenatide. Each patient received a 75-g oral glucose tolerance test (OGTT) prior to start of therapy. Factors that predicted response to therapy were identified using the area under the receiver operating characteristic curve method. RESULTS: Thirty-nine patients started and maintained the treatment goal (HbA1c < 6.5%) on metformin only, and did not require intensification of antihyperglycemic therapy; 54 patients required addition of glipizide to metformin; and 47 patients required insulin addition to metformin plus glipizide for glucose control. The plasma C-peptide concentration (C-Pep)120/C-Pep0 ratio during the OGTT was the strongest predictor of response to therapy. Patients with a ratio less than 1.78 were more likely to require insulin for glucose control, whereas patients with a ratio greater than 2.65 were more likely to achieve glucose control with metformin monotherapy. In patients started on initial triple therapy, the HbA1c decreased independently of the C-Pep120/C-Pep0 ratio. CONCLUSION: The increase in C-Pep above fasting following glucose load predicts the response to antihyperglycemic therapy in patients with new-onset diabetes. C-Pep120/C-Pep0 provides a useful tool for the individualization of antihyperglycemic therapy in patients with new-onset T2DM.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Abdelgani S, Puckett C, Adams J, et al. Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes. J Clin Endocrinol Metab. 2021. PMID: 34343296. doi:10.1210/clinem/dgab403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。